Mersana Therapeutics (MRSN) Price & Analysis

Compare

699 Followers

MRSN Stock Chart & Stats

$28.92

-$0.05(-3.28%)

At close: Jan 08 4:00 PM EST

$28.92

-$0.05(-3.28%)

Day’s Range― - ―

52-Week Range$5.21 - $57.75

Previous CloseN/A

Volume429.52K

Average Volume (3M)61.87K

Market Cap

$144.66M

Enterprise Value-$19.93M

Total Cash (Recent Filing)$56.39M

Total Debt (Recent Filing)$2.29M

Price to Earnings (P/E)―

Beta2.33

Next Earnings

Mar 04, 2026

EPS Estimate

-3.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.51

Shares Outstanding4,998,750

10 Day Avg. Volume95,463

30 Day Avg. Volume61,865

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)-18.43

Price to Sales (P/S)4.33

P/FCF Ratio-2.12

Enterprise Value/Market Cap-0.14

Enterprise Value/Revenue-0.60

Enterprise Value/Gross Profit-0.61

Enterprise Value/Ebitda0.30

Forecast

1Y Price Target

$30.75

Price Target Upside6.33% Upside

Rating ConsensusHold

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Acquisition AnnouncementDay One Biopharmaceuticals plans to acquire Mersana Therapeutics at a 182% premium over the closing price.

FDA Breakthrough Therapy DesignationBreakthrough Therapy Designation for ACC was granted by the FDA, which adds credibility to the development efforts.

Financial PerformanceThe net loss reported was better than consensus estimates of a loss of $8.3 million, or a loss of $1.54 per share.

Bears Say

Downgrade To Market PerformThe recommendation for Mersana shares has been downgraded to Market Perform.

Financial ChallengesThe book value per share is reported as negative, indicating financial challenges for the company.

Market SkepticismShort interest is at 10.6% of float, indicating some market skepticism about the stock.

Mersana Therapeutics News

Mersana Therapeutics Faces High Stakes with Potential Day One Biopharmaceuticals Merger Delays

Mersana Therapeutics (MRSN) has disclosed a new risk, in the Corporate Activity and Growth category. Mersana Therapeutics faces...

1M ago

MRSN

Mersana Therapeutics to be Acquired by Day One

Mersana Therapeutics ( ($MRSN) ) has released its Q3 earnings. Here is a breakdown of the information Mersana...

1M ago

MRSN

Morning Movers: Cidara skyrockets following Merck buyout offer

Stock futures are trading lower this morning as investors wrestle with a growing sense that the Federal Reserve...

1M ago

Mersana Therapeutics reports Q3 EPS ($1.51), consensus (89c)

Reports Q3 revenue $11M, consensus $15.5M. Cash and cash equivalents as of September 30, 2025 were $56.4 million....

1M ago

MRSN

Mersana Therapeutics downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform after the company announced an agreement to...

1M ago

MRSN

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Traders will find all of the latest stock market stories worth reading about on Thursday in our daily wrap-up. ...

1M ago

AMD

DIA

Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Michael Schmidt downgraded Mersana Therapeutics (MRSN) to Neutral from Buy after Day One Biopharmaceuticals (DAWN) agreed...

1M ago

MRSN

Mersana downgraded to Market Perform from Outperform at LifeSci Capital

LifeSci Capital analyst Charles Zhu downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform after Day One Biopharmaceuticals...

1M ago

MRSN

Hold Rating on DAWN’s Acquisition of Mersana Therapeutics: Balancing Opportunities and Risks Amid ACC Focus

LifeSci Capital analyst Charles Zhu has maintained their neutral stance on MRSN stock, giving a Hold rating yesterday....

1M ago

MRSN

Hold Rating on Mersana Therapeutics Acquisition by Day One Biopharmaceuticals: Strategic Alignment and Risk-Adjusted Valuation

Truist Financial analyst Asthika Goonewardene downgraded the rating on Mersana Therapeutics to a Hold today, setting a price...

1M ago

MRSN

Mersana Therapeutics downgraded to Market Perform from Outperform at Leerink

Leerink analyst Jonathan Chang downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform with a $29 price target...

1M ago

MRSN

Mersana Therapeutics downgraded to Hold from Buy at Truist

Truist downgraded Mersana Therapeutics (MRSN) to Hold from Buy with a price target of $30.75, down from $36,...

1M ago

MRSN

Oppenheimer says Day One paying up to $285M for Mersana ‘is interesting’

Oppenheimer analyst Matthew Biegler notes Day One (DAWN) announced it was acquiring Mersana Therapeutics (MRSN) for its B7-H4...

1M ago

DAWN

MRSN

Mersana Therapeutics downgraded to Neutral from Buy at BTIG

BTIG downgraded Mersana Therapeutics (MRSN) to Neutral from Buy following news this morning of Mersana’s acquisition by Day...

1M ago

MRSN

MRSN FAQ

What was Mersana Therapeutics Inc’s price range in the past 12 months?

Mersana Therapeutics Inc lowest stock price was $5.21 and its highest was $57.75 in the past 12 months.

What is Mersana Therapeutics Inc’s market cap?

Mersana Therapeutics Inc’s market cap is $144.66M.

When is Mersana Therapeutics Inc’s upcoming earnings report date?

Mersana Therapeutics Inc’s upcoming earnings report date is Mar 04, 2026 which is in 71 days.

How were Mersana Therapeutics Inc’s earnings last quarter?

Mersana Therapeutics Inc released its earnings results on Nov 14, 2025. The company reported -$1.51 earnings per share for the quarter, missing the consensus estimate of -$1.131 by -$0.379.

Is Mersana Therapeutics Inc overvalued?

According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mersana Therapeutics Inc pay dividends?

Mersana Therapeutics Inc does not currently pay dividends.

What is Mersana Therapeutics Inc’s EPS estimate?

Mersana Therapeutics Inc’s EPS estimate is -3.05.

How many shares outstanding does Mersana Therapeutics Inc have?

Mersana Therapeutics Inc has 4,998,750 shares outstanding.

What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?

Mersana Therapeutics Inc reported an EPS of -$1.51 in its last earnings report, missing expectations of -$1.131. Following the earnings report the stock price went up 1.786%.

Which hedge fund is a major shareholder of Mersana Therapeutics Inc?

Currently, no hedge funds are holding shares in MRSN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Mersana Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-52.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics (MRSN) Earnings & Revenues

Historic Earnings Reports

MRSN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted significant progress in clinical trials and milestone achievements, especially in the Emi-Le and XMT-2056 programs. However, challenges remain with proteinuria management and modest revenue growth, balanced by a stable financial outlook.View all MRSN earnings summaries

MRSN Stock 12 Month Forecast

Average Price Target

$30.75

▲(6.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","58":"$58","18.25":"$18.25","31.5":"$31.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,18.25,31.5,44.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.43,27.685384615384613,27.94076923076923,28.196153846153845,28.451538461538462,28.706923076923076,28.962307692307693,29.217692307692307,29.473076923076924,29.728461538461538,29.983846153846155,30.23923076923077,30.494615384615386,{"y":30.75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.43,27.685384615384613,27.94076923076923,28.196153846153845,28.451538461538462,28.706923076923076,28.962307692307693,29.217692307692307,29.473076923076924,29.728461538461538,29.983846153846155,30.23923076923077,30.494615384615386,{"y":30.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.43,27.685384615384613,27.94076923076923,28.196153846153845,28.451538461538462,28.706923076923076,28.962307692307693,29.217692307692307,29.473076923076924,29.728461538461538,29.983846153846155,30.23923076923077,30.494615384615386,{"y":30.75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >